<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-043319</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Variable presentation of autoimmune thyroid disorder in a patient treated with interferon-alpha?</dc:title>
<dc:description xml:lang="en">Interferon-&amp;#945; is the main therapeutic agent in patients with chronic active hepatitis C. Autoimmune thyroid disorders are a frequent and well-known adverse effect of interferon-&amp;#945;. We report the case of a patient with posttransfusion chronic hepatitis C treated with interferon-&amp;#945; on 2 occasions with an interval of 7 years. After the first cycle of interferon-&amp;#945; therapy she presented thyrotoxicosis due to Graves' disease with 2 relapses. After the second treatment, the patient showed hypothyroidism with positive thyroid antibodies</dc:description>
<dc:creator>Calle, H. de la</dc:creator>
<dc:creator>Barrio-Castellanos, R</dc:creator>
<dc:creator>Alonso-Blanco, M</dc:creator>
<dc:creator>Pinés-Corrales, P. J</dc:creator>
<dc:creator>Peralta-Watt, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El interferón-&amp;#945; es el principal agente terapéutico en los pacientes con hepatopatía crónica activa por el virus de la hepatitis C. Las alteraciones tiroideas autoinmunitarias constituyen un efecto secundario frecuente y bien conocido del tratamiento con interferón-&amp;#945;. Presentamos el caso de una paciente con hepatitis C crónica postrasfusional tratada con interferón-&amp;#945; en 2 ocasiones con un intervalo de 7 años. La paciente presentó, tras el primer ciclo de tratamiento con interferón-&amp;#945;, tirotoxicosis por enfermedad de Graves con recurrencia en 2 ocasiones. Después del segundo ciclo de tratamiento, la paciente presentó hipotiroidismo primario autoinmunitario</dc:description>
<dc:source>Endocrinol Nutr;53(2): 87-89, feb. 2006.</dc:source>
<dc:identifier>ibc-043319</dc:identifier>
<dc:title xml:lang="es">Disfunción tiroidea autoinmunitaria de presentación variable en una paciente tratada con interferón-alfa</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d19403^s22036</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d7217^s22036</dc:subject>
<dc:subject>^d33344^s22057</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28071^s22036</dc:subject>
<dc:subject>^d30033^s22020</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:type>article</dc:type>
<dc:date>200602</dc:date>
</metadata>
</record>
</ibecs-document>
